Capsida Receives FDA Fast Track Designation for Its Potential First-in-Class IV-Administered Gene Therapy for STXBP1 Developmental and Epileptic Encephalopathy
Capsida receives FDA IND Clearance for its first-in-class, IV-administered gene therapy for STXBP1-developmental and epileptic encephalopathy
5 Marathons in 5 Days for Charlie
Capsida Presents New GLP Toxicology Data Supporting Recent FDA IND Clearance of Its First-in-Class, IV-administered Gene Therapy for STXBP1 Developmental and Epileptic Encephalopathy
Capsida Receives FDA IND Clearance for Its First-in-Class, IV-administered Gene Therapy for STXBP1 Developmental and Epileptic Encephalopathy
Capsida to Present Progress Updates on CAP-002 at the ASGCT Annual Meeting
STXBP1 Census - Q1 2025
Small Town. Loud Voice.
What happens when a rare disease drug seems to work, but the health care system doesn’t?
